New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
08:39 EDTHEBHemispherx, Bioclones announce strategic alliance
Hemispherx Biopharma announced a strategic alliance to develop multiple projects with Bioclones. Bioclones and Hemispherx concluded strategic discussions in Johannesburg with three principal goals; initiating studies utilizing Ampligen as a potential adjuvant enhancement of Bioclones' therapeutic cancer vaccine, currently in clinical trials in Cape Town, including pre-clinical studies followed, potentially, by a Phase 1 clinical trial; seeking South African Medicine's Control Council approval to conduct trials using Alferon to eradicate the HIV virus in patients highly responsive to anti-retroviral therapy; and initiating a joint effort to obtain commercial registration of both Ampligen and Alferon in the South African markets. The first clinical program builds on the Bioclones patented therapeutic human dendritic cell, or DC, cancer vaccination approach. This invention provides a method of producing mature DCs in vitro, which comprises the step of culturing the immature DCs, thereafter exposing said cells to tumor antigens before administration to patients. The team has successfully obtained the necessary Ethics approval to use Ampligen as an adjuvant in the Bioclones pre-clinical cancer immunotherapy program utilizing patient derived samples. Pre-clinical studies will be directed towards the potential treatment of breast cancer in particular, followed by prostate cancer. These studies are part of the effort to develop patient-specific DC immunotherapy vaccines against breast cancer and prostate cancer, which elicit an immune response that will target and kill cancer cells. Human DCs matured with Ampligen and transfected with autologous tumor-specific mRNA are designed to elicit a potent and autologous tumoricidal antigen-specific cytotoxic response to the cancer.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 26, 2015
10:01 EDTHEBHemispherx says court upholds defense in case brought by Cato Capital
Hemispherx Biopharma announced that on Friday the Third Circuit Court of Appeals upheld the company's defense of a case brought by Cato Capital, one of its former investment banks, thus affirming the trial court judgment Hemispherx obtained in September 2014, when the company fully prevailed in a federal lawsuit brought against the company following trial. The appellate panel affirmed the United States District Court for the District of Delaware, which had dismissed all claims against Hemispherx and subsequently ordered Cato to pay Hemispherx attorney's fees and costs in the amount of $770,852.76.The company's President, Thomas K. Equels, stated: "We are gratified that the distinguished panel vindicated our interpretation of the contract. Our lead counsel, James J. Black, III did an outstanding job interpreting this Delaware law based agreement, and properly navigating this dispute through the courts. Now, in furtherance of our corporate policy to seek redress against plaintiffs who bring meritless claims against the company, we will pursue Cato Capital to the fullest extent of the law to collect on the award of attorney's fees and costs."
August 24, 2015
08:37 EDTHEBHemispherx enters into supply agreement with Gulf Coast Regional Blood Center
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use